IGI Logo

The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs.1,830 crore, up from Rs.1,704 crore in FY24 — a 7.4% year-on-year increase. EBITDA surged 21.6% to Rs.118 crore, and Profit After Tax jumped to Rs.118 crore, while Earnings Per Share (EPS) climbed to Rs.2.20, up 17% from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories Ltd., said:
“This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Morepen’s API business continued to dominate, contributing Rs.989 crore, while the Medical Devices segment surged to Rs.496 crore, growing 12% year-on-year. With 72% of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.

Above views are of the author and not of the website kindly read disclaimer